Moore Capital Management, LP Cytom X Therapeutics, Inc. Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $495,000 - $675,000	-75,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $185,000 - $366,000	-25,000 Reduced 25.0%	75,000 $625,000
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $184,500 - $306,250	-25,000 Reduced 20.0%	100,000 $738,000
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $2.26 Million - $3.3 Million	125,000 New	125,000 $2.31 Million

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $74.5M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.